Gilead to Acquire Arcellx for $7.8B to Accelerate Anito-cel and CAR-T Platform
Gilead will acquire Arcellx for $115 per share in cash plus a $5-per-share contingent value right (CVR), valuing the deal at about $7.8 billion and giving Gilead full control of Anito-cel, its BCMA-directed CAR-T therapy for multiple myeloma. The transaction aims to accelerate development and commercialization, with Anito-cel’s BLA accepted by the FDA and a PDUFA date of December 23, 2026; the deal is expected to close in Q2 2026 and to be accretive to EPS after FDA approval, with the CVR tied to cumulative global net sales milestones through 2029.
